Prima Biomed's primary product CVAC is targetting Ovarian Cancer not Cervical Cancer.
It has spent years developing/pioneering the delivery method.
These guys in the UK would need to spend years to sort out the delivery method. Extensive retesting during trials and would also need the drug tested for off-label usage.
They are 5+ years away from anything.
AIMHO
- Forums
- ASX - By Stock
- IMM
- new therapy for cervical cancer - uk
new therapy for cervical cancer - uk , page-2
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $480.0M |
Open | High | Low | Value | Volume |
33.0¢ | 33.5¢ | 32.0¢ | $1.703M | 5.215M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 211685 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.5¢ | 279000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 30940 | 0.320 |
3 | 63174 | 0.315 |
6 | 27370 | 0.310 |
2 | 2330 | 0.305 |
7 | 92922 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.335 | 250000 | 2 |
0.340 | 81685 | 3 |
0.345 | 207791 | 1 |
0.350 | 192258 | 4 |
0.355 | 169964 | 6 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online